ATI RN
MSN 570 Advanced Pathophysiology Final 2024
1. Which of the following characterizes ductal carcinoma in situ?
- A. It is less common than lobular carcinoma in situ.
- B. Malignant cells have not invaded the stroma.
- C. It is considered a cancer precursor.
- D. Malignant cells have not invaded the stroma; it is considered a cancer precursor and has a higher risk for invasive cancer compared to lobular carcinoma in situ.
Correct answer: D
Rationale: The correct answer is that ductal carcinoma in situ is characterized by malignant cells that have not invaded the stroma, making it a cancer precursor with a higher risk for invasive cancer compared to lobular carcinoma in situ. Choice A is incorrect because ductal carcinoma in situ is more common than lobular carcinoma in situ. Choice B is incorrect as it only partially describes ductal carcinoma in situ without mentioning its potential for progression to invasive cancer. Choice C is incorrect because it does not capture the complete characteristics of ductal carcinoma in situ, which include the risk for invasive cancer.
2. What is the treatment for patients with hemophilia A?
- A. Chemotherapy
- B. Factor VIII replacement
- C. Heparin administration
- D. Bone marrow transplant
Correct answer: B
Rationale: The correct treatment for patients with hemophilia A is Factor VIII replacement. Hemophilia A is a genetic disorder where there is a deficiency in clotting factor VIII. Therefore, replacing this factor is crucial in managing and preventing bleeding episodes. Choice A, chemotherapy, is not the correct treatment for hemophilia A. Choice C, heparin administration, is not recommended as it can further increase the risk of bleeding in patients with hemophilia. Choice D, bone marrow transplant, is not a standard treatment for hemophilia A.
3. In a 41-year-old male patient with a complex medical history diagnosed with secondary hypogonadism, which of the following health problems is the most likely etiology of his diagnosis?
- A. Type 1 diabetes
- B. Mumps
- C. An inflammatory process in the testicles
- D. Testicular trauma
Correct answer: C
Rationale: The correct answer is C: An inflammatory process in the testicles. Secondary hypogonadism in males can be caused by various factors, including an inflammatory process in the testicles. Mumps (choice B) can lead to orchitis but is less common in adults. Type 1 diabetes (choice A) is not a common cause of secondary hypogonadism. Testicular trauma (choice D) can cause primary hypogonadism but is less likely to cause secondary hypogonadism.
4. A male patient is receiving androgen therapy for the treatment of hypogonadism. What adverse effect should the nurse monitor for during this treatment?
- A. Liver dysfunction
- B. Kidney dysfunction
- C. Heart failure
- D. Pulmonary embolism
Correct answer: A
Rationale: The correct adverse effect to monitor for during androgen therapy for hypogonadism is liver dysfunction. Androgen therapy can lead to hepatotoxicity, so monitoring liver function tests is crucial during treatment. Kidney dysfunction (Choice B), heart failure (Choice C), and pulmonary embolism (Choice D) are not commonly associated with androgen therapy and are less likely adverse effects compared to liver dysfunction.
5. A male patient receiving androgen therapy is concerned about the risk of prostate cancer. What should the nurse explain about this risk?
- A. Finasteride has been shown to lower the risk of developing prostate cancer.
- B. Finasteride does not affect the risk of prostate cancer, so regular screening is unnecessary.
- C. Finasteride may increase the risk of developing prostate cancer, so regular screenings are recommended.
- D. Finasteride has no effect on the risk of prostate cancer, so regular screenings are unnecessary.
Correct answer: A
Rationale: The correct answer is A. Finasteride has been shown to lower the risk of developing prostate cancer. However, regular screenings are still recommended to monitor for any potential issues. Choice B is incorrect because finasteride has been associated with a decreased risk of prostate cancer, making regular screenings important. Choice C is incorrect as finasteride is not known to increase the risk of developing prostate cancer. Choice D is incorrect as finasteride has shown a protective effect against prostate cancer, but regular screenings are still necessary to ensure early detection and monitoring.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access